Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy

MUC1, the transmembrane glycoprotein Mucin 1, is usually found to be overexpressed in a variety of epithelial cancers playing an important role disease progression. MUC1 isoforms such as MUC1/Y, which lacks entire variable number tandem repeat region, are involved oncogenic processes by enhancing tumour initiation. MUC1/Y therefore considered promising target for identification and treatment cancers; but so far, precise remains elucidated. In this work, we developed identified DNA aptamer that specifically recognizes splice variant first time. The could bind wide human cancer cells, positive cells resulted reduced growth vitro. Moreover, inhibited breast vivo. present study highlights importance targeting unravels suitability act new therapeutic tool.